JPWO2023086893A5 - - Google Patents

Info

Publication number
JPWO2023086893A5
JPWO2023086893A5 JP2024527340A JP2024527340A JPWO2023086893A5 JP WO2023086893 A5 JPWO2023086893 A5 JP WO2023086893A5 JP 2024527340 A JP2024527340 A JP 2024527340A JP 2024527340 A JP2024527340 A JP 2024527340A JP WO2023086893 A5 JPWO2023086893 A5 JP WO2023086893A5
Authority
JP
Japan
Prior art keywords
mrna
composition
optionally
dnai1
cbf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545572A (ja
JP2024545572A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079650 external-priority patent/WO2023086893A1/en
Publication of JP2024545572A publication Critical patent/JP2024545572A/ja
Publication of JPWO2023086893A5 publication Critical patent/JPWO2023086893A5/ja
Publication of JP2024545572A5 publication Critical patent/JP2024545572A5/ja
Pending legal-status Critical Current

Links

JP2024527340A 2021-11-10 2022-11-10 原発性線毛機能不全の治療のための組成物及び方法 Pending JP2024545572A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278007P 2021-11-10 2021-11-10
US63/278,007 2021-11-10
PCT/US2022/079650 WO2023086893A1 (en) 2021-11-10 2022-11-10 Composition and methods for treatment of primary ciliary dyskinesia

Publications (3)

Publication Number Publication Date
JP2024545572A JP2024545572A (ja) 2024-12-10
JPWO2023086893A5 true JPWO2023086893A5 (https=) 2025-11-17
JP2024545572A5 JP2024545572A5 (https=) 2025-11-17

Family

ID=84829874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527340A Pending JP2024545572A (ja) 2021-11-10 2022-11-10 原発性線毛機能不全の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US20240415866A1 (https=)
EP (1) EP4429713A1 (https=)
JP (1) JP2024545572A (https=)
CN (1) CN118591398A (https=)
AU (1) AU2022388747A1 (https=)
WO (1) WO2023086893A1 (https=)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
BR112012002291A2 (pt) 2009-07-31 2016-11-29 Ethris Gmbh "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos"
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
EP3354644A1 (en) 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
ES2762873T3 (es) 2012-03-29 2020-05-26 Translate Bio Inc Lípidos catiónicos ionizables
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
EP4316588A3 (en) * 2016-05-27 2024-05-15 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
MX2019005470A (es) 2016-11-10 2019-11-21 Translate Bio Inc Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
CA3053814A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Large scale synthesis of messenger rna
EP3585892B8 (en) 2017-02-27 2022-07-13 Translate Bio, Inc. Methods for purification of messenger rna
WO2018157133A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
JP2022516356A (ja) * 2019-01-07 2022-02-25 トランスレイト バイオ, インコーポレイテッド 原発性線毛機能不全症の治療のための組成物および方法
WO2021226463A1 (en) * 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
KR20230175204A (ko) * 2021-03-22 2023-12-29 리코드 테라퓨틱스, 인크. 폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2019073557A5 (https=)
US20250145577A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
US12533402B2 (en) MRNA therapy for argininosuccinate synthetase deficiency
US20240009281A1 (en) Mrna therapy for pompe disease
US20250197463A1 (en) TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
ES2989886T3 (es) Lípidos catiónicos que comprenden una fracción esteroidal
CN114401942B (zh) 三(羟甲基)甲基甘氨酸和柠檬酸脂质
JP2017520563A5 (https=)
JP2016539916A5 (https=)
JP2016535729A5 (https=)
AU2017283479B2 (en) Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
JP2024099679A (ja) 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む2,5-ジオキソピペラジン脂質
WO2020257611A1 (en) Cationic lipids comprising an hydroxy moiety
IL270631B1 (en) Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US10780183B2 (en) Messenger RNA therapy for the treatment of Friedreich's ataxia
JP2016534992A5 (https=)
CN104519915A (zh) 肺部递送mRNA至非肺靶细胞
WO2015061491A1 (en) Mrna therapy for phenylketonuria
AU2014340083A1 (en) mRNA therapy for phenylketonuria
US12370238B2 (en) Composition and methods for treatment of primary ciliary dyskinesia
JPWO2023086893A5 (https=)
JPWO2020146344A5 (https=)
WO2024171859A1 (ja) pH応答性リン脂質
WO2026030470A1 (en) Trihydroxybenzene-containing compounds, compositions comprising trihydroxybenzene-containing compounds and related uses
JP2024545572A (ja) 原発性線毛機能不全の治療のための組成物及び方法